Regulation of endothelial nitric oxide synthase activation in endothelial cells by S1P1 and S1P3

Biochemical and Biophysical Research Communications

Volumn 476, Issue 4, 2016, Pages 627-634

  Tolle M ^a   Klockl L ^a   Wiedon, A ^a   Zidek, W ^a   van der Giet, M ^a   Schuchardt, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AUY954; Endothelial nitric oxide synthesis; FTY720P; Nitric oxide; S1P receptor; Sphingosine 1 phosphate

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RECEPTOR SUBTYPE; SERINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 3 PHOSPHATE RECEPTOR; THREONINE; UNCLASSIFIED DRUG; 3-AMINO-4-(3-HEXYLPHENYLAMINO)-4-OXOBUTYLPHOSPHONIC ACID; ANILIDE; BETA ALANINE; CAY10444; FTY 720P; NITRIC OXIDE; NOS3 PROTEIN, HUMAN; ORGANOPHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PHOSPHOSERINE; S1PR1 PROTEIN, HUMAN; SMALL INTERFERING RNA; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE RECEPTOR-3, HUMAN; THIAZOLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; PHOSPHORYLATION;

ANILIDES; BETA-ALANINE; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE KNOCKDOWN TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; ORGANOPHOSPHATES; ORGANOPHOSPHONATES; PHOSPHORYLATION; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LYSOSPHINGOLIPID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOSINE; THIAZOLIDINES; THIOPHENES;

EID: 84976643225     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.06.009     Document Type: Article

References (41)

1. [1] Triggle, C.R., Samuel, S.M., Ravishankar, S., Marei, I., Arunachalam, G., Ding, H., The endothelium: influencing vascular smooth muscle in many ways. Can. J. Physiol. Pharmacol. 90 (2012), 713–738.
2. [2] Forstermann, U., Munzel, T., Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 (2006), 1708–1714.
3. [3] Forstermann, U., Sessa, W.C., Nitric oxide synthases: regulation and function. Eur. Heart J. 33 (2012), 829–837 837a-837d.
4. [4] Dudzinski, D.M., Igarashi, J., Greif, D., Michel, T., The regulation and pharmacology of endothelial nitric oxide synthase. Annu. Rev. Pharmacol. Toxicol. 46 (2006), 235–276.
5. [5] Igarashi, J., Michel, T., Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J. Biol. Chem. 275 (2000), 32363–32370.
6. [6] Igarashi, J., Bernier, S.G., Michel, T., Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J. Biol. Chem. 276 (2001), 12420–12426.
7. [7] Schuchardt, M., Tolle, M., Prufer, J., van der Giet, M., Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br. J. Pharmacol. 163 (2011), 1140–1162.
8. [8] Waeber, C., Blondeau, N., Salomone, S., Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect. 17 (2004), 365–382.
9. [9] Igarashi, J., Michel, T., S1P and eNOS regulation. Biochim. Biophys. Acta 1781 (2008), 489–495.
10. [10] Nofer, J.R., van der Giet, M., Tolle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H.A., Tietge, U.J., Godecke, A., Ishii, I., Kleuser, B., Schafers, M., Fobker, M., Zidek, W., Assmann, G., Chun, J., Levkau, B., HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Investig. 113 (2004), 569–581.
11. [11] Morales-Ruiz, M., Lee, M.J., Zollner, S., Gratton, J.P., Scotland, R., Shiojima, I., Walsh, K., Hla, T., Sessa, W.C., Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J. Biol. Chem. 276 (2001), 19672–19677.
12. [12] Tanimoto, T., Jin, Z.G., Berk, B.C., Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem. 277 (2002), 42997–43001.
13. [13] Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., von Wnuck Lipinski, K., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., Van der Giet, M., Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. 96 (2005), 913–920.
14. [14] Schmitz, E.I., Potteck, H., Schuppel, M., Manggau, M., Wahydin, E., Kleuser, B., Sphingosine 1-phosphate protects primary human keratinocytes from apoptosis via nitric oxide formation through the receptor subtype S1P(3). Mol. Cell. Biochem. 371 (2012), 165–176.
15. [15] Igarashi, J., Miyoshi, M., Hashimoto, T., Kubota, Y., Kosaka, H., Hydrogen peroxide induces S1P1 receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate, a platelet-derived lipid mediator. Am. J. Physiol. Cell physiol. 292 (2007), C740–C748.
16. [16] Igarashi, J., Miyoshi, M., Hashimoto, T., Kubota, Y., Kosaka, H., Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 150 (2007), 470–479.
17. [17] Allende, M.L., Yamashita, T., Proia, R.L., G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102 (2003), 3665–3667.
18. [18] Chen, Z.P., Mitchelhill, K.I., Michell, B.J., Stapleton, D., Rodriguez-Crespo, I., Witters, L.A., Power, D.A., Ortiz de Montellano, P.R., Kemp, B.E., AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 443 (1999), 285–289.
19. [19] Davis, M.D., Clemens, J.J., Macdonald, T.L., Lynch, K.R., Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280 (2005), 9833–9841.
20. [20] Sanna, M.G., Wang, S.K., Gonzalez-Cabrera, P.J., Don, A., Marsolais, D., Matheu, M.P., Wei, S.H., Parker, I., Jo, E., Cheng, W.C., Cahalan, M.D., Wong, C.H., Rosen, H., Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2 (2006), 434–441.
21. [21] Lin, C.I., Chen, C.N., Lin, P.W., Lee, H., Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3. Biochem. Biophys. Res. Commun. 355 (2007), 895–901.
22. [22] Lee, M.J., Thangada, S., Claffey, K.P., Ancellin, N., Liu, C.H., Kluk, M., Volpi, M., Sha'afi, R.I., Hla, T., Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99 (1999), 301–312.
23. [23] Igarashi, J., Erwin, P.A., Dantas, A.P., Chen, H., Michel, T., VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10664–10669.
24. [24] Igarashi, J., Michel, T., Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J. Biol. Chem. 276 (2001), 36281–36288.
25. [25] Tatematsu, S., Francis, S.A., Natarajan, P., Rader, D.J., Saghatelian, A., Brown, J.D., Michel, T., Plutzky, J., Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1788–1794.
26. [26] Wilkerson, B.A., Grass, G.D., Wing, S.B., Argraves, W.S., Argraves, K.M., Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 287 (2012), 44645–44653.
27. [27] Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.X., Hobson, J.P., Rosenfeldt, H.M., Nava, V.E., Chae, S.S., Lee, M.J., Liu, C.H., Hla, T., Spiegel, S., Proia, R.L., Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Investig. 106 (2000), 951–961.
28. [28] Pan, S., Mi, Y., Pally, C., Beerli, C., Chen, A., Guerini, D., Hinterding, K., Nuesslein-Hildesheim, B., Tuntland, T., Lefebvre, S., Liu, Y., Gao, W., Chu, A., Brinkmann, V., Bruns, C., Streiff, M., Cannet, C., Cooke, N., Gray, N., A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem. Biol. 13 (2006), 1227–1234.
29. [29] Song, J., Matsuda, C., Kai, Y., Nishida, T., Nakajima, K., Mizushima, T., Kinoshita, M., Yasue, T., Sawa, Y., Ito, T., A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J. Pharmacol. Exp. Ther. 324 (2008), 276–283.
30. [30] Tsukada, Y.T., Sanna, M.G., Rosen, H., Gottlieb, R.A., S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J. Cardiovasc. Pharmacol. 50 (2007), 660–669.
31. [31] Sanna, M.G., Liao, J., Jo, E., Alfonso, C., Ahn, M.Y., Peterson, M.S., Webb, B., Lefebvre, S., Chun, J., Gray, N., Rosen, H., Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279 (2004), 13839–13848.
32. [32] Fujishiro, J., Kudou, S., Iwai, S., Takahashi, M., Hakamata, Y., Kinoshita, M., Iwanami, S., Izawa, S., Yasue, T., Hashizume, K., Murakami, T., Kobayashi, E., Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation 82 (2006), 804–812.
33. [33] van Der Lee, M.M., Bras, M., van Koppen, C.J., Zaman, G.J., beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. J. Biomol. Screen 13 (2008), 986–998.
34. [34] Thangada, S., Khanna, K.M., Blaho, V.A., Oo, M.L., Im, D.S., Guo, C., Lefrancois, L., Hla, T., Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J. Exp. Med. 207 (2010), 1475–1483.
35. [35] Pham, T.H., Okada, T., Matloubian, M., Lo, C.G., Cyster, J.G., S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28 (2008), 122–133.
36. [36] Oo, M.L., Thangada, S., Wu, M.T., Liu, C.H., Macdonald, T.L., Lynch, K.R., Lin, C.Y., Hla, T., Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282 (2007), 9082–9089.
37. [37] Oo, M.L., Chang, S.H., Thangada, S., Wu, M.T., Rezaul, K., Blaho, V., Hwang, S.I., Han, D.K., Hla, T., Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J. Clin. Investig. 121 (2011), 2290–2300.
38. [38] Jo, E., Sanna, M.G., Gonzalez-Cabrera, P.J., Thangada, S., Tigyi, G., Osborne, D.A., Hla, T., Parrill, A.L., Rosen, H., S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12 (2005), 703–715.
39. [39] Jongsma, M., van Unen, J., van Loenen, P.B., Michel, M.C., Peters, S.L., Alewijnse, A.E., Different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P(3)). Br. J. Pharmacol. 156 (2009), 1305–1311.
40. [40] Riddy, D.M., Stamp, C., Sykes, D.A., Charlton, S.J., Dowling, M.R., Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter and Ca2+ release functional assays. Br. J. Pharmacol. 167 (2012), 868–880.
41. [41] Koide, Y., Hasegawa, T., Takahashi, A., Endo, A., Mochizuki, N., Nakagawa, M., Nishida, A., Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. J. Med. Chem. 45 (2002), 4629–4638.